Genomics Biotech

Agentic AI forms collaborative in silico teams that speed drug discovery, biomarker discovery and data analysis while raising validation and governance questions.

A concise, expert overview of how AI differs from machine learning and how it accelerates drug discovery, diagnostics, and personalized treatment in biotech.

AI-enabled vascular grafts monitor blood flow in real time to detect blockages early and improve post-op care for vascular surgery patients.

At JPM 2026 Bora Pharmaceuticals and EirGenix unveiled AI-driven manufacturing, US onshoring, continuous production and biosimilar partnerships reshaping Taiwan’s biopharma role.

Insilico Medicine and Qilu Pharmaceutical launch an AI-driven collaboration worth up to $120M to discover small molecules for cardiometabolic diseases.

AI-driven drug discovery, lower rates and a looming patent cliff are set to accelerate biotech M&A in 2026. What investors and executives should watch.

Rebecca Simmons joins Qureight as COO to drive global growth of its AI CT imaging biomarkers and clinical data platform for lung and heart disease.

Servier and Insilico Medicine struck a multi-program AI oncology discovery collaboration worth up to $888M, including $32M upfront. A concise analysis of roles, strategy and realistic impact.

Insilico Medicine plans a $1 billion China hub for AI drug discovery. Analysis of why China appeals, how AI speeds discovery, and the global implications for biotech.

Discover how AI and biotechnology together drive sustainable food production, unlock revenue in alternative proteins and precision fermentation, and optimize supply chains.